Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Cash & Equivalents (2017 - 2025)

Volitionrx filings provide 10 years of Cash & Equivalents readings, the most recent being $1.1 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 65.78% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 65.78% decrease, with the full-year FY2025 number at $1.1 million, down 65.78% from a year prior.
  • Cash & Equivalents hit $1.1 million in Q4 2025 for Volitionrx, up from $199407.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $33.1 million in Q1 2021 to a low of $199407.0 in Q3 2025.
  • Median Cash & Equivalents over the past 5 years was $10.8 million (2022), compared with a mean of $12.6 million.
  • Biggest five-year swings in Cash & Equivalents: surged 559.07% in 2023 and later tumbled 96.32% in 2025.
  • Volitionrx's Cash & Equivalents stood at $20.6 million in 2021, then tumbled by 47.2% to $10.9 million in 2022, then skyrocketed by 90.76% to $20.7 million in 2023, then tumbled by 84.25% to $3.3 million in 2024, then tumbled by 65.78% to $1.1 million in 2025.
  • The last three reported values for Cash & Equivalents were $1.1 million (Q4 2025), $199407.0 (Q3 2025), and $2.3 million (Q2 2025) per Business Quant data.